Combinational drug-loaded lipid nanocapsules for the treatment of cancer

  • Int J Pharm. 2019 Oct 5;569:118588. doi: 10.1016/j.ijpharm.2019.118588.
Nikolaos Tsakiris  1 ,  Malamatenia Papavasileiou  1 ,  Elia Bozzato  1 ,  Alessandra Lopes  1 ,  Arnaud M Vigneron  2 ,  Véronique Préat  3
Affiliations
  • 1. Université Catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Avenue Mounier 73, B1.73.12, 1200 Brussels, Belgium.
  • 2. Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, Lyon, France; LabEx DEVweCAN, Université de Lyon, Lyon, France.
  • 3. Université Catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Avenue Mounier 73, B1.73.12, 1200 Brussels, Belgium. Electronic address: [email protected].
PMID: 31377406 DOI: 10.1016/j.ijpharm.2019.118588
Abstract

The purpose of this study was to investigate the feasibility of an intravenously administered combinational therapy using lipid nanocapsules (LNCs) as a drug delivery carrier for the treatment of different cancers. Therefore, we encapsulated 6 Anticancer drugs within LNCs. Their size was approximately 50 nm. Except for oxaliplatin, their encapsulation efficiency, which was measured by different analytical methods, varied between 75% for SN38 to 100% for regorafenib. The in vitro studies showed a nonsignificant difference between the cytotoxicity of free and encapsulated drugs and a significant decrease in haemolysis by encapsulation in LNCs. Finally, the in vivo experiment showed that a combinational regimen of SN38-LNCs and regorafenib-LNCs abates CT26 murine colorectal Cancer growth and increases median survival time.

Keywords
Colorectal cancer; Lipid nanocapsules; Regorafenib; SN38.
Products